$3.00
4.46% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US43906K1007
Symbol
HOOK
Sector
Industry

Hookipa Pharma, Inc. Stock price

$3.00
-0.65 17.81% 1M
-5.59 65.08% 6M
-5.10 62.96% YTD
-1.75 36.84% 1Y
-36.40 92.39% 3Y
-70.70 95.93% 5Y
-137.00 97.86% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.14 4.46%
ISIN
US43906K1007
Symbol
HOOK
Sector
Industry

Key metrics

Market capitalization $36.16m
Enterprise Value $-20.76m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales -0.42
P/S ratio (TTM) P/S ratio 0.72
P/B ratio (TTM) P/B ratio 0.50
Revenue growth (TTM) Revenue growth 143.30%
Revenue (TTM) Revenue $50.00m
EBIT (operating result TTM) EBIT $-45.75m
Cash position $77.15m
EPS (TTM) EPS $-3.99
P/E forward negative
P/S forward 0.90
EV/Sales forward negative
Short interest 0.47%
Show more

Is Hookipa Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Hookipa Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Hookipa Pharma, Inc. forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Hookipa Pharma, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Hookipa Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
50 50
143% 143%
100%
- Direct Costs - -
-
-
47 47
169% 169%
93%
- Selling and Administrative Expenses - -
-
-
- Research and Development Expense 77 77
7% 7%
153%
- -
-
-
- Depreciation and Amortization 3.33 3.33
5% 5%
7%
EBIT (Operating Income) EBIT -46 -46
43% 43%
-92%
Net Profit -43 -43
37% 37%
-87%

In millions USD.

Don't miss a Thing! We will send you all news about Hookipa Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hookipa Pharma, Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safety Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durabl...
Neutral
GlobeNewsWire
16 days ago
Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024 Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024
Neutral
GlobeNewsWire
17 days ago
Study done in collaboration with Memorial Sloan Kettering and led by Dr. Winston Wong, Head and Neck Oncologist and Dr. Alan Ho, Chief of the Head and Neck Oncology Service
More Hookipa Pharma, Inc. News

Company Profile

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its product includes VaxWace and TheraT. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, Katherine Cohen, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.

Head office United States
CEO Malte Peters
Employees 151
Founded 2011
Website www.hookipapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today